What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors anticipating news from the company's ongoing pivotal trial lifted the stock ahead of an investment bank presentation.
This August, Celldex enrolled the last of 327 women with triple-negative breast cancer and tumors that overexpress gpNMB, a cell surface protein the company's lead candidate targets. Glembatumumab vedotin, or glemba, shakes hands with gpNMB on its way into tumor cells where it delivers a lethal dose of chemo.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Stock
€39.00
-4.370%
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 61 € shows a very positive potential of 56.41% compared to the current price of 39.0 € for Celldex Therapeutics.
